secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0000950170-24-078159
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa: MRT-2359 dose update; MRT-6160 IND for autoimmune diseases
----------------------------------------------------------------------

- MRT-2359 Phase 1/2: favorable safety at 0.5 mg 21/7 schedule; evaluating 0.75 mg cohort; RP2D and updated data expected H2 2024.
- IND submitted for MRT-6160, VAV1-directed MGD for systemic/neurological autoimmune diseases; Phase 1 SAD/MAD starts summer 2024 with data Q1 2025.
- MRT-2359 potential RP2D of 0.5 mg using 21 days on/7 days off regimen, allowing twice as frequent dosing per cycle vs prior schedule.
- MRT-6160 is first rationally designed MGD for non-oncology indication; preclinical efficacy in IBD, RA, MS models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024078159/0000950170-24-078159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024078159/glue-20240627.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-078159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer